[{"id":"2d273f1a-d076-4196-b160-67a7c935aa6c","acronym":"NCI-2014-01488","url":"https://clinicaltrials.gov/study/NCT02208362","created_at":"2021-03-16T19:52:14.281Z","updated_at":"2025-02-25T14:06:49.902Z","phase":"Phase 1","brief_title":"Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma","source_id_and_acronym":"NCT02208362 - NCI-2014-01488","lead_sponsor":"City of Hope Medical Center","biomarkers":" IL13RA2","pipe":" | ","alterations":" CD123 expression","tags":["IL13RA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MB-101"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 05/18/2015","start_date":" 05/18/2015","primary_txt":" Primary completion: 02/08/2021","primary_completion_date":" 02/08/2021","study_txt":" Completion: 07/08/2025","study_completion_date":" 07/08/2025","last_update_posted":"2025-02-19"},{"id":"36e68fbc-8506-4572-acf5-3e86f4ea808b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05949125","created_at":"2023-08-14T10:11:12.134Z","updated_at":"2025-02-25T15:28:11.863Z","phase":"Phase 1","brief_title":"Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies","source_id_and_acronym":"NCT05949125","lead_sponsor":"AvenCell Europe GmbH","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 expression","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • AVC-201"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 01/03/2024","start_date":" 01/03/2024","primary_txt":" Primary completion: 05/01/2027","primary_completion_date":" 05/01/2027","study_txt":" Completion: 01/01/2028","study_completion_date":" 01/01/2028","last_update_posted":"2025-02-10"},{"id":"610f01eb-c68e-44f8-9b23-e46ae4e5528c","acronym":"GO-TAG","url":"https://clinicaltrials.gov/study/NCT05716009","created_at":"2023-02-08T18:00:15.099Z","updated_at":"2025-02-25T15:27:53.038Z","phase":"Phase 1","brief_title":"Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Patients With Relapsed/Refractory AML","source_id_and_acronym":"NCT05716009 - GO-TAG","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" CD33 • IL3RA","pipe":" | ","alterations":" CD123 expression","tags":["CD33 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mylotarg (gemtuzumab ozogamicin) • Elzonris (tagraxofusp-erzs)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 11/20/2023","start_date":" 11/20/2023","primary_txt":" Primary completion: 12/25/2027","primary_completion_date":" 12/25/2027","study_txt":" Completion: 12/25/2028","study_completion_date":" 12/25/2028","last_update_posted":"2025-02-10"},{"id":"9604cfb1-e6e8-49f6-8502-880d232ccb42","acronym":"","url":"https://clinicaltrials.gov/study/NCT03113643","created_at":"2023-08-14T10:10:56.859Z","updated_at":"2024-07-02T16:34:27.434Z","phase":"Phase 1","brief_title":"SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)","source_id_and_acronym":"NCT03113643","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 expression • IL3RA expression","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 expression • IL3RA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • Elzonris (tagraxofusp-erzs)"],"overall_status":"Recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 06/26/2017","start_date":" 06/26/2017","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 05/31/2026","study_completion_date":" 05/31/2026","last_update_posted":"2024-06-11"},{"id":"9436a8ff-5aa6-4f94-a70c-ecf2cecaa874","acronym":"NCI-2022-02215","url":"https://clinicaltrials.gov/study/NCT05285813","created_at":"2023-08-14T10:11:07.915Z","updated_at":"2024-07-02T16:34:58.922Z","phase":"Phase 2","brief_title":"A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure","source_id_and_acronym":"NCT05285813 - NCI-2022-02215","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 positive • CD123 expression • IL3RA expression","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive • CD123 expression • IL3RA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vibecotamab (XmAb14045)"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 05/06/2022","start_date":" 05/06/2022","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-06-04"},{"id":"93a602fc-fef4-4ca8-ada5-f9aa24df7e29","acronym":"","url":"https://clinicaltrials.gov/study/NCT05720988","created_at":"2023-08-14T10:11:11.619Z","updated_at":"2025-02-25T15:45:00.769Z","phase":"Phase 1","brief_title":"Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia","source_id_and_acronym":"NCT05720988","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" CD123 • IL3RA","pipe":" | ","alterations":" CD123 positive • CD123 expression • IL3RA expression","tags":["CD123 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive • CD123 expression • IL3RA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • Elzonris (tagraxofusp-erzs)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 08/03/2024","start_date":" 08/03/2024","primary_txt":" Primary completion: 08/03/2025","primary_completion_date":" 08/03/2025","study_txt":" Completion: 08/03/2026","study_completion_date":" 08/03/2026","last_update_posted":"2024-03-08"},{"id":"883417c3-4016-4ca7-adfb-379f14c7fc53","acronym":"","url":"https://clinicaltrials.gov/study/NCT05476770","created_at":"2023-08-14T10:11:09.445Z","updated_at":"2024-07-02T16:35:18.062Z","phase":"Phase 1","brief_title":"Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies","source_id_and_acronym":"NCT05476770","lead_sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 expression","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • azacitidine • vincristine • fludarabine IV • Elzonris (tagraxofusp-erzs)"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 11/11/2022","start_date":" 11/11/2022","primary_txt":" Primary completion: 11/11/2025","primary_completion_date":" 11/11/2025","study_txt":" Completion: 11/11/2027","study_completion_date":" 11/11/2027","last_update_posted":"2024-02-22"},{"id":"f9804601-1b5e-4001-940c-6e9301ecc5f3","acronym":"CP-MGD024-01","url":"https://clinicaltrials.gov/study/NCT05362773","created_at":"2022-05-05T15:53:53.535Z","updated_at":"2024-07-02T16:35:23.328Z","phase":"Phase 1","brief_title":"A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies","source_id_and_acronym":"NCT05362773 - CP-MGD024-01","lead_sponsor":"MacroGenics","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 expression • IL3RA expression","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 expression • IL3RA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MGD024"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 07/13/2022","start_date":" 07/13/2022","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2024-01-17"},{"id":"a498e32c-b2f0-40fb-8597-93fddf2b2869","acronym":"","url":"https://clinicaltrials.gov/study/NCT06034275","created_at":"2023-09-13T14:09:45.731Z","updated_at":"2024-07-02T16:35:23.633Z","phase":"Phase 1","brief_title":"Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies","source_id_and_acronym":"NCT06034275","lead_sponsor":"Vincerx Pharma, Inc.","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 expression • IL3RA expression","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 expression • IL3RA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VIP943"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 09/13/2023","start_date":" 09/13/2023","primary_txt":" Primary completion: 05/30/2025","primary_completion_date":" 05/30/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-01-12"},{"id":"2e1f45d7-114f-4454-9867-53cc8e8641d4","acronym":"","url":"https://clinicaltrials.gov/study/NCT04681105","created_at":"2021-01-19T20:46:40.489Z","updated_at":"2024-07-02T16:35:25.698Z","phase":"Phase 1","brief_title":"Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies","source_id_and_acronym":"NCT04681105","lead_sponsor":"City of Hope Medical Center","biomarkers":" PD-L1 • IL3RA","pipe":" | ","alterations":" CD123 expression","tags":["PD-L1 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e flotetuzumab (MGD006)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 13","initiation":"Initiation: 11/18/2020","start_date":" 11/18/2020","primary_txt":" Primary completion: 05/05/2026","primary_completion_date":" 05/05/2026","study_txt":" Completion: 05/05/2026","study_completion_date":" 05/05/2026","last_update_posted":"2023-12-20"},{"id":"50591c7e-2bb2-4a10-8880-29d3224dc148","acronym":"PEPN1812","url":"https://clinicaltrials.gov/study/NCT04158739","created_at":"2023-12-11T17:16:23.292Z","updated_at":"2024-07-02T16:35:26.619Z","phase":"Phase 1","brief_title":"Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT04158739 - PEPN1812","lead_sponsor":"Children's Oncology Group","biomarkers":" CD123 • IL3RA","pipe":" | ","alterations":" CD123 expression • IL3RA expression","tags":["CD123 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 expression • IL3RA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • flotetuzumab (MGD006) • Starasid (cytarabine ocfosfate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 01/22/2020","start_date":" 01/22/2020","primary_txt":" Primary completion: 09/30/2022","primary_completion_date":" 09/30/2022","study_txt":" Completion: 09/22/2024","study_completion_date":" 09/22/2024","last_update_posted":"2023-12-11"},{"id":"50192133-c8e8-4b6f-9edf-895d64f162f6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05995041","created_at":"2023-08-16T16:08:27.797Z","updated_at":"2024-07-02T16:35:33.734Z","phase":"Phase 1","brief_title":"Universal CAR-T Cells Targeting AML","source_id_and_acronym":"NCT05995041","lead_sponsor":"Shenzhen Geno-Immune Medical Institute","biomarkers":" CD38 • CD33 • IL3RA","pipe":" | ","alterations":" CD123 expression","tags":["CD38 • CD33 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 10/31/2023","start_date":" 10/31/2023","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2023-10-12"},{"id":"f871fea9-e2b8-4a4c-97ed-93bea378ea0b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04510051","created_at":"2021-01-18T21:37:11.984Z","updated_at":"2024-07-02T16:35:34.277Z","phase":"Phase 1","brief_title":"CAR T Cells After Lymphodepletion for the Treatment of IL13Rα2 Positive Recurrent or Refractory Brain Tumors in Children","source_id_and_acronym":"NCT04510051","lead_sponsor":"City of Hope Medical Center","biomarkers":" CD123","pipe":" | ","alterations":" CD123 expression","tags":["CD123"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 12/04/2020","start_date":" 12/04/2020","primary_txt":" Primary completion: 08/24/2024","primary_completion_date":" 08/24/2024","study_txt":" Completion: 08/24/2024","study_completion_date":" 08/24/2024","last_update_posted":"2023-10-09"},{"id":"8d195ac4-ff45-457f-b006-0abe5f018000","acronym":"","url":"https://clinicaltrials.gov/study/NCT06006403","created_at":"2023-08-23T15:10:48.638Z","updated_at":"2024-07-02T16:35:38.691Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm","source_id_and_acronym":"NCT06006403","lead_sponsor":"Chongqing Precision Biotech Co., Ltd","biomarkers":" IL6 • CD123 • IL3RA","pipe":" | ","alterations":" CD123 positive • CD123 expression • IL3RA positive","tags":["IL6 • CD123 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive • CD123 expression • IL3RA positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • CD123 targeted CAR-NK"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 08/31/2023","start_date":" 08/31/2023","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 08/31/2026","study_completion_date":" 08/31/2026","last_update_posted":"2023-08-30"},{"id":"7c0994a9-8277-4f13-b963-37bb1082d426","acronym":"CADENZA","url":"https://clinicaltrials.gov/study/NCT03386513","created_at":"2023-08-14T10:10:58.304Z","updated_at":"2024-07-02T16:35:41.144Z","phase":"Phase 1/2","brief_title":"Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN","source_id_and_acronym":"NCT03386513 - CADENZA","lead_sponsor":"ImmunoGen, Inc.","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 positive • CD123 expression • IL3RA expression","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive • CD123 expression • IL3RA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pivekimab sunirine (PVEK)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 179","initiation":"Initiation: 01/02/2018","start_date":" 01/02/2018","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-08-03"},{"id":"c42189ed-78b6-4d92-90b3-d29c29267002","acronym":"","url":"https://clinicaltrials.gov/study/NCT04923919","created_at":"2023-08-14T10:11:05.758Z","updated_at":"2024-07-02T16:35:43.069Z","phase":"Phase 1","brief_title":"Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Myeloid Leukemia","source_id_and_acronym":"NCT04923919","lead_sponsor":"920th Hospital of Joint Logistics Support Force of People's Liberation Army of China","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 expression","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 09/14/2021","start_date":" 09/14/2021","primary_txt":" Primary completion: 12/05/2024","primary_completion_date":" 12/05/2024","study_txt":" Completion: 12/05/2024","study_completion_date":" 12/05/2024","last_update_posted":"2023-07-13"},{"id":"23fe5699-b91c-473a-b6f8-99a276ffb074","acronym":"","url":"https://clinicaltrials.gov/study/NCT04272125","created_at":"2021-01-18T20:45:10.451Z","updated_at":"2024-07-02T16:35:50.369Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy of CD123-Targeted CAR-T Therapy for Relapsed/Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT04272125","lead_sponsor":"Chongqing Precision Biotech Co., Ltd","biomarkers":" CD123 • IL3RA","pipe":" | ","alterations":" CD123 positive • CD123 expression • IL3RA expression • IL3RA positive","tags":["CD123 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive • CD123 expression • IL3RA expression • IL3RA positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 CAR-T cell therapy"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 12/01/2019","start_date":" 12/01/2019","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2023-04-18"},{"id":"2f6c09fe-648a-43a4-b8de-c7035dd17c75","acronym":"","url":"https://clinicaltrials.gov/study/NCT04265963","created_at":"2021-01-18T20:43:42.945Z","updated_at":"2024-07-02T16:35:50.304Z","phase":"Phase 1/2","brief_title":"CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT04265963","lead_sponsor":"Chongqing Precision Biotech Co., Ltd","biomarkers":" CD123 • IL3RA","pipe":" | ","alterations":" CD123 positive • CD123 expression • IL3RA expression • IL3RA positive","tags":["CD123 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive • CD123 expression • IL3RA expression • IL3RA positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 CAR-T cell therapy"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 09/01/2019","start_date":" 09/01/2019","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2023-04-18"},{"id":"01bdc6f6-0410-48c7-88ae-60f097419d24","acronym":"","url":"https://clinicaltrials.gov/study/NCT03585517","created_at":"2023-08-14T10:10:59.415Z","updated_at":"2024-07-02T16:35:57.376Z","phase":"Phase 1","brief_title":"Safety and Efficacy Evaluation of IM23 CAR-T Cells (IM23CAR-T)","source_id_and_acronym":"NCT03585517","lead_sponsor":"Beijing Immunochina Medical Science \u0026 Technology Co., Ltd.","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 expression","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • IM23"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 07/21/2018","start_date":" 07/21/2018","primary_txt":" Primary completion: 08/01/2020","primary_completion_date":" 08/01/2020","study_txt":" Completion: 10/01/2020","study_completion_date":" 10/01/2020","last_update_posted":"2023-01-19"},{"id":"25e63b7a-328c-4c51-a48a-0d3138ffc567","acronym":"","url":"https://clinicaltrials.gov/study/NCT05388305","created_at":"2023-08-14T10:11:08.756Z","updated_at":"2024-07-02T16:36:09.855Z","phase":"","brief_title":"Universal CAR-γδT Cell Injection in the AML Patients","source_id_and_acronym":"NCT05388305","lead_sponsor":"Hebei Senlang Biotechnology Inc., Ltd.","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 expression","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 04/20/2022","start_date":" 04/20/2022","primary_txt":" Primary completion: 04/30/2023","primary_completion_date":" 04/30/2023","study_txt":" Completion: 05/30/2023","study_completion_date":" 05/30/2023","last_update_posted":"2022-05-26"},{"id":"ef9f33ba-d081-412c-af8d-bf768df5b986","acronym":"","url":"https://clinicaltrials.gov/study/NCT02715011","created_at":"2021-01-18T13:16:28.170Z","updated_at":"2024-07-02T16:36:25.083Z","phase":"Phase 1","brief_title":"Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)","source_id_and_acronym":"NCT02715011","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" CD123 • IL3RA","pipe":" | ","alterations":" CD123 expression • IL3RA expression","tags":["CD123 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 expression • IL3RA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JNJ-63709178"],"overall_status":"Completed","enrollment":" Enrollment 62","initiation":"Initiation: 06/01/2016","start_date":" 06/01/2016","primary_txt":" Primary completion: 03/26/2021","primary_completion_date":" 03/26/2021","study_txt":" Completion: 03/26/2021","study_completion_date":" 03/26/2021","last_update_posted":"2021-08-31"},{"id":"e4d83257-c80b-4e1e-8b12-fb24718335d7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03739606","created_at":"2021-01-18T18:18:56.025Z","updated_at":"2024-07-02T16:36:37.235Z","phase":"Phase 2","brief_title":"Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer","source_id_and_acronym":"NCT03739606","lead_sponsor":"City of Hope Medical Center","biomarkers":" PD-L1 • IL3RA","pipe":" | ","alterations":" CD123 expression","tags":["PD-L1 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e flotetuzumab (MGD006)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 10/20/2020","start_date":" 10/20/2020","primary_txt":" Primary completion: 10/20/2020","primary_completion_date":" 10/20/2020","study_txt":" Completion: 10/20/2020","study_completion_date":" 10/20/2020","last_update_posted":"2020-12-17"},{"id":"d2dd03bc-0fae-46dc-868b-5c48fa14ca32","acronym":"","url":"https://clinicaltrials.gov/study/NCT04010877","created_at":"2021-01-18T19:42:18.741Z","updated_at":"2024-07-02T16:36:55.454Z","phase":"Phase 1/2","brief_title":"Multiple CAR-T Cell Therapy Targeting AML","source_id_and_acronym":"NCT04010877","lead_sponsor":"Shenzhen Geno-Immune Medical Institute","biomarkers":" CD33 • IL3RA","pipe":" | ","alterations":" CD123 expression","tags":["CD33 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 08/01/2019","start_date":" 08/01/2019","primary_txt":" Primary completion: 07/31/2021","primary_completion_date":" 07/31/2021","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2019-09-19"},{"id":"fb7d666c-54c6-4059-a090-52088390aea8","acronym":"","url":"https://clinicaltrials.gov/study/NCT02937103","created_at":"2021-01-18T14:25:20.027Z","updated_at":"2024-07-02T16:36:58.622Z","phase":"Phase 1/2","brief_title":"A Clinical Research of CD123-Targeted CAR-T in Myeloid Malignancies","source_id_and_acronym":"NCT02937103","lead_sponsor":"Southwest Hospital, China","biomarkers":" CD123 • IL3RA","pipe":" | ","alterations":" CD123 expression • IL3RA expression","tags":["CD123 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 expression • IL3RA expression"],"overall_status":"Unknown status","enrollment":" Enrollment 45","initiation":"Initiation: 10/01/2016","start_date":" 10/01/2016","primary_txt":" Primary completion: 10/01/2019","primary_completion_date":" 10/01/2019","study_txt":" Completion: 10/01/2020","study_completion_date":" 10/01/2020","last_update_posted":"2019-06-25"}]